In contrast, data from King’s College London and the United Network for Organ Sharing suggest that HFE and non-HFE OLT recipients have comparable survival, with HCC recurrence contributing to a minority of patient deaths.21 22 These studies are limited by a large number of confounding variables, which might explain the variation in their findings, including baseline tumour number, tumour type and volume at the time of listing, AFP level, type of locoregional therapy used as a bridge to transplantation, and length of time on the waiting list. This evidence concerns the gene AFP and hepatocellular carcinoma.